Head-To-Head Contrast: Venus Concept (NASDAQ:VERO) and Embecta (NASDAQ:EMBC)

Venus Concept (NASDAQ:VERO) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Venus Concept and Embecta”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88 million	0.01	-$47.00 million	($48.84)	-0.01
Embecta	$1.08 billion	0.30	$95.40 million	$1.48	3.93

Embecta has higher revenue and earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 1.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Venus Concept and Embecta, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1	0	0	0	1.00
Embecta	2	3	0	0	1.60

Embecta has a consensus price target of $11.00, indicating a potential upside of 89.17%. Given Embecta’s stronger consensus rating and higher probable upside, analysts plainly believe Embecta is more favorable than Venus Concept.

Profitability

This table compares Venus Concept and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Embecta	8.59%	-19.25%	10.82%

Summary

Embecta beats Venus Concept on 12 of the 13 factors compared between the two stocks.

About Venus Concept

Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.